CO5611129A2 - Co-terapia con oxazolidinona - Google Patents

Co-terapia con oxazolidinona

Info

Publication number
CO5611129A2
CO5611129A2 CO04069502A CO04069502A CO5611129A2 CO 5611129 A2 CO5611129 A2 CO 5611129A2 CO 04069502 A CO04069502 A CO 04069502A CO 04069502 A CO04069502 A CO 04069502A CO 5611129 A2 CO5611129 A2 CO 5611129A2
Authority
CO
Colombia
Prior art keywords
group
substituent
optionally substituted
vitamin
oxazolidinone
Prior art date
Application number
CO04069502A
Other languages
English (en)
Inventor
Michael John Dupuis
John Thomas Herberg
Joseph Patrick Martin Jr
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of CO5611129A2 publication Critical patent/CO5611129A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1.- Un método para tratar un paciente que requiera oxazolidinona mediante la administración de una cantidad eficaz de oxazolidinona y una cantidad eficaz de al menos una vitamina, seleccionada del grupo consistente en vitamina B2, vitamina B6, vitamina B12 y ácido fólico.2.- El método de la reivindicación 1, en el que la oxazolidinona tiene la fórmula general I:y sus sales farmacéuticamente aceptables;en la cual X se selecciona del grupo consistente en un grupo alquilo-C1-10 (estando el grupo alquilo opcionalmente sustituido con al menos un sustituyente R4), un grupo alqueniloC2-10 (estando el grupo alquenilo opcionalmente sustituido con al menos un sustituyente R4), un grupo alquinilo-C2-10 (estando el grupo alquinilo opcionalmente sustituido con al menos un sustituyente R4), un grupo cicloalquilo-C3-7 (estando el grupo cicloalquilo opcionalmente sustituido con al menos un sustituyente R5), un grupo cicloalquenilo-C3-7 (estando el grupo cicloalquenilo opcionalmente sustituido con al menos un sustituyente R5), un grupo arilo-C5-7 (estando el grupo arilo opcionalmente sustituido con al menos un sustituyente R5), y un grupo heterocíclico-C3-7 saturado o insaturado, que contiene al menos un heteroátomo seleccionado de O, S y N (estando el grupo heterocíclico opcionalmente sustituido con al menos un sustituyente R5); ...
CO04069502A 2002-01-25 2004-07-22 Co-terapia con oxazolidinona CO5611129A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35162802P 2002-01-25 2002-01-25

Publications (1)

Publication Number Publication Date
CO5611129A2 true CO5611129A2 (es) 2006-02-28

Family

ID=27663011

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04069502A CO5611129A2 (es) 2002-01-25 2004-07-22 Co-terapia con oxazolidinona

Country Status (16)

Country Link
US (1) US20030171331A1 (es)
EP (1) EP1467734A1 (es)
JP (1) JP2005523896A (es)
KR (1) KR20040078133A (es)
CN (1) CN1633292A (es)
AR (1) AR038211A1 (es)
BR (1) BR0307205A (es)
CA (1) CA2473457A1 (es)
CO (1) CO5611129A2 (es)
MX (1) MXPA04007161A (es)
NO (1) NO20043603L (es)
PL (1) PL371438A1 (es)
RU (1) RU2004122700A (es)
TW (1) TW200302095A (es)
WO (1) WO2003063862A1 (es)
ZA (1) ZA200405720B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0227701D0 (en) * 2002-11-28 2003-01-08 Astrazeneca Ab Chemical compounds
WO2005005398A2 (en) 2003-07-02 2005-01-20 Merck & Co., Inc. Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof
BRPI0416645A (pt) * 2003-11-24 2007-01-16 Interdigital Tech Corp método e aparelho para utilizar antena de feixe direcional em unidade de transmissão e recepção sem fio
PE20060619A1 (es) 2004-07-29 2006-07-11 Ferrer Int Derivados de oxazolidinona como antibacterianos
ATE449773T1 (de) 2005-06-29 2009-12-15 Pharmacia & Upjohn Co Llc Homomorpholinoxazolidinone als antibakterielle mittel
WO2008069619A1 (en) * 2006-12-08 2008-06-12 Legochem Bioscience Ltd. Novel oxazolidinone derivatives, process for preparing thereof and pharmaceutical composition containing the same
CN102861022A (zh) * 2012-10-16 2013-01-09 北京诚创思达医药科技有限公司 一种盐酸维拉唑酮复方制剂
WO2015068171A1 (en) * 2013-11-08 2015-05-14 Lee Pharma Limited Novel oxazolidinone compounds
JP6286536B2 (ja) * 2013-11-08 2018-02-28 リー ファーマ リミテッドＬｅｅ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ 新規オキサゾリジノン抗菌化合物
WO2017066964A1 (en) 2015-10-22 2017-04-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL29597A (en) * 1968-03-07 1969-07-30 Doron A A feed premix composition
GB1222708A (en) * 1968-10-22 1971-02-17 Delalande Sa Novel 5-(n-substituted aminomethyl)-2-oxazolidinones and their process of preparation
US4053593A (en) * 1975-11-26 1977-10-11 Lew Frumoff Medical product combining antimicrobial, antiporasitic and vitamin complex
LU80081A1 (fr) * 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4705799A (en) * 1983-06-07 1987-11-10 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl benzenes useful as antibacterial agents
DE3639225A1 (de) * 1986-11-14 1988-05-19 Schering Ag Verwendung von 5-(subst. phenyl)-oxazolidinonderiaten als psychopharmaka
US5043443A (en) * 1988-07-29 1991-08-27 Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives
US5182403A (en) * 1988-09-15 1993-01-26 The Upjohn Company Substituted 3(5'indazolyl) oxazolidin-2-ones
US5225565A (en) * 1988-09-15 1993-07-06 The Upjohn Company Antibacterial 3-(fused-ring substituted)phenyl-5β-amidomethyloxazolidin-2-ones
US5164510A (en) * 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
US5231188A (en) * 1989-11-17 1993-07-27 The Upjohn Company Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents
JP2669579B2 (ja) * 1991-10-23 1997-10-29 エーザイ株式会社 オキサゾリドン誘導体
DK0610265T3 (da) * 1991-11-01 1997-06-09 Upjohn Co Substituerede aryl- og heteroarylphenyloxazolidioner, som kan anvendes som antibakterielle midler
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
ATE161833T1 (de) * 1992-12-08 1998-01-15 Upjohn Co Durch eine tropon gruppe substituierte phenyloxazolidinone-derivate als antibakterielles mittel
CN1086138A (zh) * 1993-03-20 1994-05-04 何亚长 一种治胃、十二指肠溃疡病药物及其制造方法
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
WO1995014684A1 (en) * 1993-11-22 1995-06-01 The Upjohn Company Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones
US5668286A (en) * 1994-03-15 1997-09-16 Pharmacia & Upjohn Company Oxazolidinone derivatives and pharmaceutical compositions containing them
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
DE4425612A1 (de) * 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
DE4425609A1 (de) * 1994-07-20 1996-01-25 Bayer Ag Benzofuranyl- und Benzothienyloxazolidinone
CN1046520C (zh) * 1994-11-15 1999-11-17 法玛西雅厄普约翰美国公司 二环噁嗪及噻嗪噁唑烷酮抗菌剂
DE19531321A1 (de) * 1995-08-25 1997-02-27 Merck Patent Gmbh Piperidinylmethyloxazolidinone
KR100463772B1 (ko) * 1995-09-01 2005-11-09 파마시아 앤드 업존 캄파니 엘엘씨 4내지8원헤테로사이클릭환에탄소-탄소결합을갖는페닐옥사졸리디논
DE19601264A1 (de) * 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19604223A1 (de) * 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
CN1136950A (zh) * 1996-03-18 1996-12-04 胡安全 一种治疗胃肠溃疡、胃肠炎的药物组合物及其生产方法
US6255304B1 (en) * 1997-05-30 2001-07-03 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
CN1060044C (zh) * 1997-12-23 2001-01-03 李伟 一种治疗肠胃疾病的药
WO1999037630A1 (en) * 1998-01-23 1999-07-29 Versicor, Inc. Oxazolidinone combinatorial libraries, compositions and methods of preparation
CN1071115C (zh) * 1998-08-07 2001-09-19 彭小平 一种治疗胃肠炎及溃疡的复方药
CN1072953C (zh) * 1998-12-04 2001-10-17 金建社 一种治疗消化系统疾病的药物及其制备方法
CN1072959C (zh) * 1999-01-04 2001-10-17 界文光 一种治疗胃炎、胃溃疡及十二指肠溃疡药物的制备方法
CN1293956A (zh) * 1999-10-31 2001-05-09 边庆瑞 一种快速根治胃病的配方
CN1363280A (zh) * 2002-01-15 2002-08-14 泰安市山农大药业有限公司 肉鸡肠毒综合症防治组合物

Also Published As

Publication number Publication date
KR20040078133A (ko) 2004-09-08
RU2004122700A (ru) 2005-04-10
MXPA04007161A (es) 2004-10-29
ZA200405720B (en) 2005-11-18
PL371438A1 (en) 2005-06-13
BR0307205A (pt) 2004-12-07
JP2005523896A (ja) 2005-08-11
TW200302095A (en) 2003-08-01
NO20043603L (no) 2004-08-24
CN1633292A (zh) 2005-06-29
CA2473457A1 (en) 2003-08-07
WO2003063862A1 (en) 2003-08-07
AR038211A1 (es) 2005-01-05
EP1467734A1 (en) 2004-10-20
US20030171331A1 (en) 2003-09-11

Similar Documents

Publication Publication Date Title
CO2019000069A2 (es) Agentes antivirales contra la hepatitis b
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
AR109590A2 (es) Régimen posológico para inhibidores de comt
CO2018009561A2 (es) Métodos para tratar la depresión con antagonistas del receptor de orexina-2
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
AR060089A1 (es) Tratamiento del dolor
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
BR112019003710A2 (pt) inibidor de pde7, composto, composição farmacêutica, uso de um inibidor de pde7 ou de um composto, e, método para tratar ou prevenir uma doença que é melhorada pela inibição de pde7.
CO5611129A2 (es) Co-terapia con oxazolidinona
CL2023003662A1 (es) Activadores de dimetoxifenilalquilamina de receptores de serotonina
BR112019023981A2 (pt) injeção de octreotida
AR113922A1 (es) Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
CO2022008690A2 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
CL2020003143A1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
PA8597501A1 (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol
AR076617A1 (es) Compuestos de aminopirazol triazolotiadiazol inhibidores de la proteina quinasa c-met.
AR046874A1 (es) Nuevos metodos
AR039977A1 (es) Composicion a base de diclofenac para el tratamiento topico de afecciones de la cavidad orofaringea
AR114306A1 (es) Tratamiento y prevención de trastornos del sueño
CR8584A (es) Piperazinas derivadas de urea para el tratamiento de la endometrosis

Legal Events

Date Code Title Description
FC Application refused